Document Detail

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
MedLine Citation:
PMID:  22778174     Owner:  NLM     Status:  Publisher    
AimsCinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator. This study evaluated the haemodynamic effect and safety of cinaciguat added to standard therapy in patients with acute decompensated heart failure (ADHF).Methods and resultsIn this placebo-controlled, phase IIb study (NCT00559650), 139 patients admitted with ADHF, pulmonary capillary wedge pressure (PCWP) ≥18 mmHg, left ventricular ejection fraction <40%, and a pre-existing need for invasive haemodynamic monitoring were randomized 2:1 to cinaciguat:placebo (continuous i.v. infusion). The dose was titrated for 8 h and maintained for 16-40 h (starting dose: 100 μg/h). At 8 h, mean PCWP changed from 25.7 ± 5.0 mmHg by -7.7 mmHg with cinaciguat and from 25.0 ± 5.3 mmHg by -3.7 mmHg with placebo (P < 0.0001). The mean right atrial pressure changed from 12.4 ± 5.3 mmHg by -2.7 mmHg with cinaciguat and from 11.8 ± 4.9 mmHg by -0.6 mmHg with placebo (P= 0.0019). Cinaciguat also decreased the pulmonary and systemic vascular resistance and the mean arterial pressure, and increased the cardiac index (all P < 0.0001 vs. placebo). Systolic blood pressure changed by -21.6 ± 17.0 mmHg with cinaciguat and -5.0 ± 14.5 mmHg with placebo. Adverse events were experienced by 71 and 45% of patients receiving cinaciguat and placebo, respectively. No adverse effects on the 30-day mortality were seen; however, the trial was stopped prematurely due to an increased occurrence of hypotension at cinaciguat doses ≥200 µg/h.ConclusionCinaciguat unloaded the heart in patients with ADHF. However, high doses were associated with hypotension.
Erland Erdmann; Marc J Semigran; Markku S Nieminen; Mihai Gheorghiade; Rahul Agrawal; Veselin Mitrovic; Alexandre Mebazaa
Related Documents :
22844584 - Effects of telmisartan with hydrochlorothiazide versus valsartan with hydrochlorothiazi...
16272814 - An appropriate indication for the initiation of beta-blocker therapy in dilated cardiom...
8582664 - Prooxidant activity of beta-carotene under 100% oxygen pressure in rat liver microsomes.
22845774 - Improvement of intradialytic hypotension in diabetic hemodialysis patients using vitami...
19474184 - Inhibition of natriuretic factors increases blood pressure in rats.
7468064 - Effects of aortic occlusion in heparinized and non-heparinized pigs.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-9
Journal Detail:
Title:  European heart journal     Volume:  -     ISSN:  1522-9645     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Herzzentrum der Universität zu Köln, Cologne, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies.
Next Document:  Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous corona...